Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of Lutathera in Recurrent/Progressive High-Grade CNS Tumors and Meningiomas
NCT05278208Phase 2Recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Nov 2022
- Primary completion
- Nov 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in central nervous system tumor, meningioma, sponsored by Nationwide Children's Hospital. Started Nov 2022; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
central nervous system tumormeningioma
Beyond the preview
Go deeper on NCT05278208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278208.